Compare SXTP & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXTP | VIVS |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.8M |
| IPO Year | 2023 | 2010 |
| Metric | SXTP | VIVS |
|---|---|---|
| Price | $0.90 | $0.16 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.70 | N/A |
| AVG Volume (30 Days) | 126.3K | ★ 670.2K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,005,471.00 | ★ $4,603,000.00 |
| Revenue This Year | N/A | $228,144.28 |
| Revenue Next Year | $70.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 65.49 | 8.82 |
| 52 Week Low | $0.34 | $0.15 |
| 52 Week High | $8.62 | $3.40 |
| Indicator | SXTP | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 36.73 | 23.53 |
| Support Level | $0.84 | N/A |
| Resistance Level | $1.63 | $0.30 |
| Average True Range (ATR) | 0.14 | 0.02 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 2.63 | 1.84 |
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.